Our analysis of the HD21 Older Cohort is now published in the JCO @ascocancer.bsky.social doi.org/10.1200/JCO-... @ferdinandusj.bsky.social 🎉 Key take away: PET-guided 4-6x BrECADD is feasible and highly effective in older AS-cHL patients 60-75 years of age, thereby expanding treatment options 🧵👀👇

6x Nivo-AVD with PFS & OS benefit and better tolerability vs 6x BV-AVD in AS-HL pts ≥60 years in the randomised S1826 trial. Efficacy driven by EBV status? PRO-CTCAE confirming better tolerability & revealing discrepancy to physician reporting @ascocancer.bsky.social ascopubs.org/doi/10.1200/...

Among patients with chronic lymphocytic leukemia, undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial results: nej.md/3SMNdC4  

#EHA2025

Heartfelt congrats to David, Roland and the whole @uniklinikkoeln.bsky.social lymphoma team! Great to see our exciting study on targeting CSF1R+ myeloid-monocytic cells to overcome CAR-T cell resistance now published online in Cancer Cell @cp-cancercell.bsky.social: doi.org/10.1016/j.cc... 🎉

Please appreciate this post by Paul on the new Beyond Maximum Grade Commission Series on AE Reporting in the Lancet Haematology.

A comprehensive update on the pivotal paper from 2018, which should inform physicians and trialists alike!

#lymsm #lymphoma #leukemia #meded

Announcing the 1st paper of ‪@thelancethaem.bsky.social‬ Commission on Adverse Events, with Drs. @biostatgirl.bsky.social‬ & Thanarajasingam.

We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.

buff.ly/SchRHhq
Thread ⬇️🧵

Late breaking at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial: nej.md/4mh5RPL

@ascocancer.bsky.social

Happy to share our systematic Cochrane review on vaccines for preventing infections in patients with hematological malignancies: doi.org/10.1002/1465... In light of infection-related morbidity and non-relapse mortality in our patients, this is an important issue where we lack high-quality evidence.

Apart from COVID-19–related adverse events, the triple combination was well tolerated. buff.ly/ARqMYrh #clinicaltrialsandobservations #lymphoidneoplasia #hemesky

Honored to write a Commentary in @natrevclinoncol.bsky.social on recent progress, unmet needs and future perspectives in Hodgkin lymphoma: rdcu.be/ecWQh: "The positive results of HD21 & S1826 should not curb but rather spark further practice-changing research for the benefit of all patients with HL"

“...to care is an act not of weakness, but of strength.”

The Lancet response: bit.ly/4jRb5Av

LAST CHANCE to register & join us for our Post-ASH 2024 #CLL Highlights Webinar taking place TOMORROW🩸

Presentations & discussions on selected abstracts from #ASH24

Prof. Barbara Eichhorst, Dr Matthew Davids & Dr Kerry Rogers

👉https://buff.ly/4hSDgxY

#CLLsm #LeuSM

Comprehensive interdisciplinary review on current and emerging therapeutic targets to treat immune-related adverse events (irAE). A rapidly evolving field of high clinical relevance elegantly summarized by Jessica Hassel and colleagues @dkfz.bsky.social @cellpress.bsky.social doi.org/10.1016/j.it...